Lung Cancer Trial, Not Yet Recruiting NCT07392073 Sponsor: Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine Condition: Lung Cancer
Back to Lung Cancer

Lung Cancer Trial, Not Yet Recruiting

NCT07392073
Not Yet Recruiting Not Applicable

voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice

Who may and may not be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who may be able to join

  • People who have been diagnosed with advanced (stage IIIB or IV) non-small cell lung cancer, confirmed by laboratory analysis of tissue or cell samples
  • People who are planned to receive a combination of an immune therapy drug (a PD-1 inhibitor, such as pembrolizumab) together with platinum-based chemotherapy (such as pemetrexed and carboplatin)
  • People aged between 18 and 80 years old
  • People who are reasonably active and able to carry out daily activities, with only mild limitations from their illness (confirm with trial site)
  • People who are expected to live for at least 12 weeks
  • People whose bone marrow is producing enough blood cells, based on specific blood test results (confirm with trial site for exact values)
  • People whose liver and kidneys are functioning well enough, based on specific blood test results (confirm with trial site for exact values)
  • People who have at least one tumour that can be measured on a scan, according to standard research measurement guidelines
  • People who are able to give informed consent and are willing and able to take part in all study activities, including regular blood draws and follow-up scans

Who may not be able to join

Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.

  • People who do not have any tumours that can be measured on a scan using standard research guidelines
  • People experiencing serious cancer-related emergencies that require immediate treatment, such as pressure on the spinal cord or blockage of a major vein in the chest
  • People who have cancer that has spread to the brain or the lining of the brain or spinal cord, and this has not yet been treated or is not currently under control
  • People who have received immune checkpoint inhibitor treatment within the 4 weeks before joining the trial
  • People who regularly take immune-suppressing medications, such as steroid tablets at a dose greater than 10 mg per day of prednisone or equivalent
  • People who have blood clotting problems shown by specific blood test results, or who are currently taking blood-thinning medication (confirm with trial site for exact values)
  • People whose veins are too difficult to access for the regular blood draws required by the study
  • People with active hepatitis B (with a high level of the virus in the blood), active hepatitis C, or HIV infection
  • People with an active bacterial or fungal infection that requires ongoing treatment with systemic (whole-body) medication
  • People who are pregnant or currently breastfeeding
  • People with a severe psychiatric condition or communication difficulties that would prevent them from giving informed consent or completing follow-up requirements

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 14 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Not Yet Recruiting
Phase
Not Applicable
Sponsor
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Registry
ClinicalTrials.gov
Start date
1 April 2026
Est. completion
1 April 2028

Primary endpoints

Progression-Free Survival (PFS)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 14 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov